- The advanced AI co-pilot reduces uncertainty and inaccuracies, ultimately resulting in better, more predictable clinical trials
- The collaboration will embed multimodal and multiscale agentic AI into clinical workflows
- This partnership reflects a shared commitment to using predictive technology to simulate clinical trials and accelerate effective treatments, and transform patient lives
Zurich, Switzerland, 24 June, 2025– Polaroid Therapeutics (PTx), the Swiss-based biotech company, today announced its strategic partnership with Ingenix.AI, a multimodal and multiscale generative Artificial Intelligence (AI) co-pilot for clinical development. This collaboration brings together PTx’s versatile clinical research portfolio for APTTM (Antimicrobial Polymer Technology) and Ingenix.AI’s powerful AI engine to simulate clinical trials on digital twins of the human body. Ingenix.AI’s technology allows PTx’s team to analyze data ranging from molecular to cellular and population levels to enhance its wound management clinical trial efforts.
PTx and Ingenix.AI share a common goal in leveraging technology to improve patient outcomes. By working together, the companies will produce more accurate predictive insights that increase certainty, optimize efficiency, and expedite PTx’s mission to deliver a new generation of wound care therapies to patients who need them most.
The cutting-edge agentic AI co-pilot for clinical development is designed to support investigators by integrating multiscale data sources, surfacing biological mechanisms, flagging risks, and streamlining positive outcomes of any future clinical trials.
The companies are jointly exploring the potential impact on future clinical study designs and regulatory interactions. All data and insights gathered from Ingenix.AI co-pilot will be heavily scrutinized by a board of clinical experts to validate Ingenix.AI’s AI model within the existing PTx clinical workflows.
“Our partnership with Ingenix.AI marks a pivotal step in scaling and advancing how we design and deliver our clinical trials with APTTM in wound management” comments Ran Frenkel, CEO and Co-Founder of PTx. “Our work together goes beyond AI integration into our process. It is a shared belief in leveraging technology to ultimately improve patient care and outcomes. By combining our intensive clinical research program and iNGENIX.AI’s unique technology, pioneering it for the first time in the world in advanced wound management, we are developing better solutions for patients sooner. “
“We are excited to partner with Polaroid Therapeutics, as this marks a milestone in our journey – from making groundbreaking advances in AI research to delivering tangible value to the pharmaceutical industry and, ultimately, to patients,” said Piotr Surma, CEO of Ingenix. “We believe our platform, with its explainability and deep understanding of multiscale biological phenomena, will help Polaroid Therapeutics to significantly de-risk their clinical development.”
ENDS
EDITORS NOTES
About PTx:
Polaroid Therapeutics is a Swiss-based biotech start-up in the development of innovative antimicrobial technology. Incubated and spun off by Polaroid, the brand that pioneered the chemistry behind analogue instant photography. Polaroid Therapeutics’ mission is to bring to life the best of Polaroid’s vision of creating a more human and meaningful world through cutting-edge technology and research.
Founded in 2022, Polaroid Therapeutics is developing antimicrobial therapies based on proprietary antibacterial antimicrobial technology to prevent and inhibit infections in multiple indications, such as acute and chronic wounds. This proprietary platfrom APTTM (Antimicrobial Polymer Technology) is a breakthrough solution that does not create promote antimicrobial resistance (AMR) – regarded as the most prominent global threat to health.
Contact:
Liam Rawson
About Ingenix.AI:
Founded by a team with a $200M exit and built by 25 top-tier AI scientists and computational biologists, Ingenix’s mission is to de-risk clinical trials. We’re developing an AI-powered simulation of drug safety and efficacy grounded in biological mechanisms. In objective benchmark tests, our models have outperformed some of the most advanced AI systems currently used by the pharmaceutical industry.
Contact:
Piotr Surma